Quality

High Concentration of Mesenchymal Stem Cells (MSCs) and Hematopoietic Stem Cells (HSCs)

Higher cell concentration means more cells with potential healing power are delivered to the application site. The Harvest® Bone Marrow Aspirate Concentrate (BMAC®) System generates higher concentrations of nucleated cells than iliac crest autograft. The total nucleated cell count found in the product generated from the Harvest BMAC system is typically three to six times that of bone marrow aspirate (BMA).10

This chart shows the high concentration of nucleated cells in the product from the Harvest BMAC system as compared to alternatives.

Average Cell Capture of Iliac Crest Autograft10
Measured in Total Nucleated Cells (TNCs)/mL

Iliac Crest Autograft

53 × 106

Harvest BMAC System: Cell Concentration Versus BMA  

Measured in TNCs/mL

BMA

Harvest BMAC Product

22 × 106

84 × 106

A standard 10 mL sample product from the Harvest BMAC system provides upward of 850 million TNCs and over 5 billion platelets.34 Compared with other concentrated BMA products, the product from the Harvest BMAC system delivers greater concentrations of TNCs and stem cells.2,10 Results may vary.

A typical sample of a product from the Harvest BMAC system contains the following concentrations of stem cells and platelets:

Composition of Product from the Harvest BMAC System36,37,44

Cell Type

% of TNCs*

BMAC Conc./mL

MSCs†

0.001%

1,500 to 3,000 CFUs**
3,526 CFUs**

HSCs‡

1%

0.8 to 1.5 × 106
800 ×106

Platelets

N/A

600 to 900 × 106   
752 ×106

*TNCs = total nucleated cells; platelets do not contain a nucleus
**CFUs = colony forming units—the gold standard assay for measuring MSC concentration
†MSCs = mesenchymal stem cells
‡HSCs = hematopoietic stem cells

A Less Invasive Approach

There has been a shift from traditional repair surgery to more sophisticated treatment methods, including both less invasive surgical techniques and the use of biologic therapies.

Iliac crest autograft is a highly invasive procedure performed in the operating room that can generate significant donor site morbidity. In contrast, the Harvest BMAC system provides a less invasive solution that can be performed quickly and easily in a hospital or office setting.40

Not All BMA Systems Are Created Equal

The chart below is adapted from a series of studies evaluating the composition of concentrated BMA produced by different commercially available systems.

Concentration Systems are not Equal

Final Concentrate

Harvest® SmartPrep® Multicellular Processing System

Arteriocyte (Magellan®)

P Value

Nucleated cells (million/mL)

90.80 ± 48.90

38.17 ± 22.58

<0.001

NCC Yield %

65.07 ± 19.29

32.55 ± 13.72

<0.001

CFU/mL

1,270 ± 1,009

514 ± 355

0.004

Hegde et al. 2013 AAOS Poster by Hospital for Special Surgery

Final Concentrate

SmartPrep System

Biomet (BioCUE™)

P Value

Nucleated cells (million/mL)

101.48 ± 64.13

90.81 ± 61.05

0.766

NCC Yield %

65.07 ± 19.29

62.34 ± 28.29

0.725

CFU/mL

1,270 ± 1,009

134 ± 158

<0.001

Hegde et al. 2013 AAOS Poster by Hospital for Special Surgery

Final Concentrate

SmartPrep System

EmCyte (Elite™)

Nucleated cells (million/mL)

75.40 ± 38.0

63.10 ± 51.40

NCC Yield %

69.50 ± 4.10

45.40 ± 23.30

Kevy, Jacobson, Albano 2014 Blood Research Institute

Final Concentrate

SmartPrep System

Thermogenesis (Res-Q™)

Nucleated cells (million/mL)

78.30 ± 33.50

50.70 ± 16.30

NCC Yield %

67.30 ± 10.20

43.40 ± 17.30

CFU/mL

4,969 ± 9,240

2,966 ± 4,146

Kevy, Jacobson, Albano 2014 Blood Research Institute

Final Concentrate

SmartPrep System

Cytomedix (Angel®)

Nucleated cells (million/mL)

98.10 ± 61.90

20.50 ± 11.20

NCC Yield %

70.80 ± 6.0

16.10 ± 1.10

CFU/mL

3,526 ± 1,856

1,559 ± 533

Kevy, Jacobson, Albano 2014 Blood Research Institute